Hemostemix (CVE:HEM) Stock Price Down 11.8% – Time to Sell?

Hemostemix Inc. (CVE:HEM)’s stock price fell 11.8% during mid-day trading on Thursday . The stock traded as low as C$0.08 and last traded at C$0.08. 386,862 shares traded hands during trading, an increase of 538% from the average session volume of 60,618 shares. The stock had previously closed at C$0.09.

Hemostemix Price Performance

The company has a current ratio of 1.54, a quick ratio of 0.48 and a debt-to-equity ratio of -99.52. The company has a market capitalization of C$15.08 million, a P/E ratio of -2.96 and a beta of 0.25. The stock has a 50 day moving average price of C$0.09 and a 200 day moving average price of C$0.09.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.